Genprex Shares Jump 14% Pre-Market on FDA Fast Track Designation
By Ben Glickman Shares of Genprex were higher early Wednesday after the company said it had received Fast Track Designation from the U.S. Food and Drug...
Stay updated with breaking news from Track Designations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Ben Glickman Shares of Genprex were higher early Wednesday after the company said it had received Fast Track Designation from the U.S. Food and Drug...
HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for surufatinib for the treatment of pancreatic (“pNETs”) and ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Share: – EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval – HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ("EMA") has validated and accepted its marketing authorization application ("MAA") for surufatinib for the treatment of ...